On January 6, 2026, AngioDynamics raised its fiscal 2026 net sales guidance to US$312 million–US$314 million and reported narrower losses on higher quarterly sales, while also disclosing that ...
Discover how to test for multi-user vulnerabilities. Four real-world examples of tenant isolation, consolidated testing, and ...
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback